$AGIO
Agios Pharmaceuticals Inc Stock $agio

$agio Overview Financials Valuation SEC Filings Company Website

2018 Q4 Form 10-Q Financial Statement

#000143922218000018 Filed on November 01, 2018

Income Statement

Concept	2018 Q4	2018 Q3	2017 Q3
Revenue	$30.01M	$15.20M	$11.36M
YoY Change	206.29%	33.81%	26.41%
Cost Of Revenue	$700.0K	$695.0K	$0.00
YoY Change
Gross Profit	$29.31M	$14.50M	$11.36M
YoY Change		27.69%
Gross Profit Margin	97.66%	95.43%	100.0%
Selling, General & Admin	$31.86M	$31.10M	$17.46M
YoY Change	40.29%	78.12%	47.34%
% of Gross Profit	108.7%	214.44%	153.72%
Research & Development	$93.81M	$82.56M	$72.92M
YoY Change	21.48%	13.23%	20.24%
% of Gross Profit	320.06%	569.27%	641.99%
Depreciation & Amortization	$1.900M	$1.800M	$1.600M
YoY Change	18.75%	12.5%	14.29%
% of Gross Profit	6.48%	12.41%	14.09%
Operating Expenses	$125.7M	$114.4M	$90.38M
YoY Change	25.76%	26.54%	24.66%
Operating Profit	-$96.36M	-$99.16M	-$79.02M
YoY Change	6.91%	25.49%	24.41%
Interest Expense	$4.560M	$4.500M	$1.880M
YoY Change	146.49%	139.36%	176.47%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income	-$91.79M	-$94.66M	-$77.14M
YoY Change	3.96%	22.71%	22.78%
Income Tax
% Of Pretax Income
Net Earnings	-$91.79M	-$94.66M	-$77.14M
YoY Change	3.96%	22.72%	22.76%
Net Earnings / Revenue	-305.83%	-622.87%	-679.14%
Basic Earnings Per Share
Diluted Earnings Per Share	-$1.577M	-$1.631M	-$1.592M
COMMON SHARES
Basic Shares Outstanding	58.18M shares	57.99M shares	48.39M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2018 Q4	2018 Q3	2017 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$585.3M	$669.9M	$507.9M
YoY Change	38.08%	31.9%	-12.29%
Cash & Equivalents	$70.50M	$156.5M	$132.7M
Short-Term Investments	$514.8M	$513.4M	$375.2M
Other Short-Term Assets	$17.20M	$16.50M	$15.30M
YoY Change	-1.71%	7.84%	48.54%
Inventory	$869.0K	$863.0K
Prepaid Expenses
Receivables	$7.300M	$4.500M	$700.0K
Other Receivables	$3.100M	$3.800M	$4.400M
Total Short-Term Assets	$613.8M	$695.5M	$528.3M
YoY Change	37.85%	31.65%	-12.09%
LONG-TERM ASSETS
Property, Plant & Equipment	$24.32M	$24.61M	$24.02M
YoY Change	-0.45%	2.47%	-8.54%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$220.1M	$208.5M	$133.8M
YoY Change	53.06%	55.83%	207.59%
Other Assets	$238.0K	$416.0K	$1.070M
YoY Change	-73.29%	-61.12%	-20.09%
Total Long-Term Assets	$244.7M	$233.5M	$158.9M
YoY Change	44.66%	46.98%	123.48%
TOTAL ASSETS
Total Short-Term Assets	$613.8M	$695.5M	$528.3M
Total Long-Term Assets	$244.7M	$233.5M	$158.9M
Total Assets	$858.5M	$929.1M	$687.2M
YoY Change	39.72%	35.2%	2.26%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$17.88M	$16.62M	$17.90M
YoY Change	-21.47%	-7.17%	16.05%
Accrued Expenses	$42.15M	$25.30M	$30.76M
YoY Change	23.85%	-17.74%	34.86%
Deferred Revenue	$32.71M	$42.14M
YoY Change	-13.56%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$93.50M	$84.75M	$88.11M
YoY Change	-1.51%	-3.82%	12.96%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$77.40M	$84.10M	$149.3M
YoY Change	-46.25%	-43.67%	-22.48%
Total Long-Term Liabilities	$77.40M	$84.10M	$149.3M
YoY Change	-46.25%	-43.67%	-22.48%
TOTAL LIABILITIES
Total Short-Term Liabilities	$93.50M	$84.75M	$88.11M
Total Long-Term Liabilities	$77.40M	$84.10M	$149.3M
Total Liabilities	$170.9M	$168.9M	$237.4M
YoY Change	-28.45%	-28.87%	-12.27%
SHAREHOLDERS EQUITY
Retained Earnings	-$1.105B	-$1.013B	-$709.8M
YoY Change	38.41%	42.7%	66.35%
Common Stock	$1.794B	$1.775B	$1.160B
YoY Change	52.72%	53.02%	40.09%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$687.5M	$760.2M	$449.8M
YoY Change
Total Liabilities & Shareholders Equity	$858.5M	$929.1M	$687.2M
YoY Change	39.72%	35.2%	2.26%

Cashflow Statement

Concept	2018 Q4	2018 Q3	2017 Q3
OPERATING ACTIVITIES
Net Income	-$91.79M	-$94.66M	-$77.14M
YoY Change	3.96%	22.72%	22.76%
Depreciation, Depletion And Amortization	$1.900M	$1.800M	$1.600M
YoY Change	18.75%	12.5%	14.29%
Cash From Operating Activities	-$74.20M	-$63.80M	-$77.70M
YoY Change	-0.27%	-17.89%	58.57%
INVESTING ACTIVITIES
Capital Expenditures	-$1.100M	-$3.100M	-$2.000M
YoY Change	-15.38%	55.0%	-41.18%
Acquisitions
YoY Change
Other Investing Activities	-$11.70M	$5.900M	$68.40M
YoY Change	-127.15%	-91.37%	-215.35%
Cash From Investing Activities	-$12.80M	$2.800M	$66.40M
YoY Change	-130.55%	-95.78%	-205.9%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	1.000M	7.200M	5.300M
YoY Change	-61.54%	35.85%	-96.75%
NET CHANGE
Cash From Operating Activities	-74.20M	-63.80M	-77.70M
Cash From Investing Activities	-12.80M	2.800M	66.40M
Cash From Financing Activities	1.000M	7.200M	5.300M
Net Change In Cash	-86.00M	-53.80M	-6.000M
YoY Change	187.63%	796.67%	-111.65%
FREE CASH FLOW
Cash From Operating Activities	-$74.20M	-$63.80M	-$77.70M
Capital Expenditures	-$1.100M	-$3.100M	-$2.000M
Free Cash Flow	-$73.10M	-$60.70M	-$75.70M
YoY Change	0.0%	-19.82%	66.01%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Entity Registrant Name EntityRegistrantName	AGIOS PHARMACEUTICALS INC
	dei	Trading Symbol TradingSymbol	AGIO
	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
	dei	Document Period End Date DocumentPeriodEndDate	2018-09-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2018
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Amendment Flag AmendmentFlag	false
	dei	Entity Central Index Key EntityCentralIndexKey	0001439222
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2018Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2017Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2018Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	25000000	shares
CY2017Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	25000000	shares
CY2018Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2017Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2018Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2017Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2018Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2017Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2018Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	125000000	shares
CY2017Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	125000000	shares
CY2018Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	58167932	shares
CY2017Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	48826153	shares
CY2018Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	58167932	shares
CY2017Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	48826153	shares
CY2017Q3	us-gaap	Research And Development Arrangement Contract To Perform For Others Compensation Earned ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned	1078000	USD
	us-gaap	Research And Development Arrangement Contract To Perform For Others Compensation Earned ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned	6343000	USD
	dei	Document Type DocumentType	10-Q
CY2018Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	58178676	shares
CY2018Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	156478000	USD
CY2017Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	102724000	USD
CY2018Q3	us-gaap	Available For Sale Securities Current AvailableForSaleSecuritiesCurrent	513414000	USD
CY2017Q4	us-gaap	Available For Sale Securities Current AvailableForSaleSecuritiesCurrent	321212000	USD
CY2018Q3	us-gaap	Contract With Customer Asset Net Current ContractWithCustomerAssetNetCurrent	2631000	USD
CY2017Q4	us-gaap	Contract With Customer Asset Net Current ContractWithCustomerAssetNetCurrent	0	USD
CY2018Q3	agio	Collaboration Receivable Duefrom Related Parties Current CollaborationReceivableDuefromRelatedPartiesCurrent	3395000	USD
CY2017Q4	agio	Collaboration Receivable Duefrom Related Parties Current CollaborationReceivableDuefromRelatedPartiesCurrent	2448000	USD
CY2018Q3	agio	Collaboration Receivable Other Current CollaborationReceivableOtherCurrent	440000	USD
CY2017Q4	agio	Collaboration Receivable Other Current CollaborationReceivableOtherCurrent	0	USD
CY2018Q3	agio	Royalty Receivable Duefrom Related Parties Current RoyaltyReceivableDuefromRelatedPartiesCurrent	1863000	USD
CY2017Q4	agio	Royalty Receivable Duefrom Related Parties Current RoyaltyReceivableDuefromRelatedPartiesCurrent	1222000	USD
CY2018Q3	us-gaap	Inventory Net InventoryNet	863000	USD
CY2017Q4	us-gaap	Inventory Net InventoryNet	0	USD
CY2018Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	16458000	USD
CY2017Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	17655000	USD
CY2018Q3	us-gaap	Assets Current AssetsCurrent	695542000	USD
CY2017Q4	us-gaap	Assets Current AssetsCurrent	445261000	USD
CY2018Q3	us-gaap	Available For Sale Securities Noncurrent AvailableForSaleSecuritiesNoncurrent	208508000	USD
CY2017Q4	us-gaap	Available For Sale Securities Noncurrent AvailableForSaleSecuritiesNoncurrent	143814000	USD
CY2018Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	24613000	USD
CY2017Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	24431000	USD
CY2018Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	416000	USD
CY2017Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	891000	USD
CY2018Q3	us-gaap	Assets Assets	929079000	USD
CY2017Q4	us-gaap	Assets Assets	614397000	USD
CY2018Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	16616000	USD
CY2017Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	22767000	USD
CY2018Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	25303000	USD
CY2017Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	34031000	USD
CY2018Q3	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	42141000	USD
CY2017Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	37842000	USD
CY2018Q3	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent	686000	USD
CY2017Q4	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent	301000	USD
CY2018Q3	us-gaap	Liabilities Current LiabilitiesCurrent	84746000	USD
CY2017Q4	us-gaap	Liabilities Current LiabilitiesCurrent	94941000	USD
CY2018Q3	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	66294000	USD
CY2017Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	125798000	USD
CY2018Q3	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	17826000	USD
CY2017Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	18155000	USD
CY2018Q3	us-gaap	Liabilities Liabilities	168866000	USD
CY2017Q4	us-gaap	Liabilities Liabilities	238894000	USD
CY2018Q3	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2017Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2018Q3	us-gaap	Common Stock Value CommonStockValue	58000	USD
CY2017Q4	us-gaap	Common Stock Value CommonStockValue	49000	USD
CY2018Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1775113000	USD
CY2017Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1174904000	USD
CY2018Q3	us-gaap	Accumulated Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-2119000	USD
CY2017Q4	us-gaap	Accumulated Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-1389000	USD
CY2018Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1012839000	USD
CY2017Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-798061000	USD
CY2018Q3	us-gaap	Stockholders Equity StockholdersEquity	760213000	USD
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	375503000	USD
CY2018Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	929079000	USD
CY2017Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	614397000	USD
CY2018Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	15198000	USD
CY2017Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	11358000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	64374000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	33212000	USD
CY2018Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	695000	USD
CY2017Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	0	USD
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	695000	USD
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	0	USD
CY2018Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	82561000	USD
CY2017Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	72917000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	247515000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	215465000	USD
CY2018Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	31104000	USD
CY2017Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	17458000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	82287000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	48411000	USD
CY2018Q3	us-gaap	Operating Expenses OperatingExpenses	114360000	USD
CY2017Q3	us-gaap	Operating Expenses OperatingExpenses	90375000	USD
	us-gaap	Operating Expenses OperatingExpenses	330497000	USD
	us-gaap	Operating Expenses OperatingExpenses	263876000	USD
CY2018Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-99162000	USD
CY2017Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-79017000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-266123000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-230664000	USD
CY2018Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	4498000	USD
CY2017Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	1880000	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	11889000	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	4279000	USD
CY2018Q3	us-gaap	Net Income Loss NetIncomeLoss	-94664000	USD
CY2017Q3	us-gaap	Net Income Loss NetIncomeLoss	-77137000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-254234000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-226385000	USD
CY2018Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.63
CY2017Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.59
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-4.45
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-4.94
CY2018Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	58033386	shares
CY2017Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	48459424	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	57158492	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	45851203	shares
CY2018Q3	us-gaap	Net Income Loss NetIncomeLoss	-94664000	USD
CY2017Q3	us-gaap	Net Income Loss NetIncomeLoss	-77137000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-254234000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-226385000	USD
CY2018Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	279000	USD
CY2017Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	135000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-730000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-202000	USD
CY2018Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-94385000	USD
CY2017Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-77002000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-254964000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-226587000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-254234000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-226385000	USD
	us-gaap	Depreciation Depreciation	5261000	USD
	us-gaap	Depreciation Depreciation	4778000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	55170000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	35128000	USD
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	2540000	USD
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-25000	USD
	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	20000	USD
	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	-40000	USD
	agio	Increase Decrease In Contract With Customer Asset IncreaseDecreaseInContractWithCustomerAsset	2631000	USD
	agio	Increase Decrease In Contract With Customer Asset IncreaseDecreaseInContractWithCustomerAsset	0	USD
	agio	Increase Decreasein Collaboration Receivable Duefrom Related Parties Current IncreaseDecreaseinCollaborationReceivableDuefromRelatedPartiesCurrent	947000	USD
	agio	Increase Decreasein Collaboration Receivable Duefrom Related Parties Current IncreaseDecreaseinCollaborationReceivableDuefromRelatedPartiesCurrent	-1397000	USD
	agio	Increase Decreasein Collaboration Receivable Other Current IncreaseDecreaseinCollaborationReceivableOtherCurrent	440000	USD
	agio	Increase Decreasein Collaboration Receivable Other Current IncreaseDecreaseinCollaborationReceivableOtherCurrent	0	USD
	agio	Increase Decreasein Royalty Receivable Duefrom Related Parties Current IncreaseDecreaseinRoyaltyReceivableDuefromRelatedPartiesCurrent	641000	USD
	agio	Increase Decreasein Royalty Receivable Duefrom Related Parties Current IncreaseDecreaseinRoyaltyReceivableDuefromRelatedPartiesCurrent	715000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	863000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	0	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-1711000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1886000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-5830000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	742000	USD
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-8537000	USD
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-1242000	USD
	agio	Increase Decrease In Contract With Customer Liability Related Party IncreaseDecreaseInContractWithCustomerLiabilityRelatedParty	-15749000	USD
	agio	Increase Decrease In Contract With Customer Liability Related Party IncreaseDecreaseInContractWithCustomerLiabilityRelatedParty	-20141000	USD
	us-gaap	Increase Decrease In Deferred Charges IncreaseDecreaseInDeferredCharges	-56000	USD
	us-gaap	Increase Decrease In Deferred Charges IncreaseDecreaseInDeferredCharges	2519000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-230234000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-210778000	USD
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	755368000	USD
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	604525000	USD
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	500281000	USD
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	508116000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	5933000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	3347000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-261020000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-99756000	USD
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	391000	USD
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	89000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	516206000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	270250000	USD
	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	29193000	USD
	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	12360000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	545008000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	282521000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	53754000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-28013000	USD
CY2017Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	102724000	USD
CY2016Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	160754000	USD
CY2018Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	156478000	USD
CY2017Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	132741000	USD
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	501000	USD
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	226000	USD
	agio	Proceeds From Stock Options Exercised In Other Current Assets ProceedsFromStockOptionsExercisedInOtherCurrentAssets	39000	USD
	agio	Proceeds From Stock Options Exercised In Other Current Assets ProceedsFromStockOptionsExercisedInOtherCurrentAssets	95000	USD
	agio	Public Offering Costs In Other Assets PublicOfferingCostsInOtherAssets	0	USD
	agio	Public Offering Costs In Other Assets PublicOfferingCostsInOtherAssets	318000	USD
CY2018Q1	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	8152986	shares
CY2018Q1	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	67.00
CY2018Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	516200000	USD
CY2018Q3	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	878400000	USD
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;">Concentrations of credit risk </span></div><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Financial instruments which potentially subject us to credit risk consist primarily of cash, cash equivalents, and marketable securities. We hold these investments in highly rated financial institutions, and, by policy, limit the amounts of credit exposure to any one financial institution. These amounts at times may exceed federally insured limits. We have not experienced any credit losses in such accounts and do not believe we are exposed to any significant credit risk on these funds. We have no off-balance sheet concentrations of credit risk, such as foreign currency exchange contracts, option contracts, or other hedging arrangements.</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">We are also subject to credit risk on our receivables, including trade receivables from our customers and collaboration and royalty receivables from Celgene Corporation, or Celgene, and CStone Pharmaceuticals, or CStone. Concentrations of credit risk with respect to receivables, which are typically unsecured, are somewhat mitigated due to the number of customers using our products. Our trade receivables arise from product sales in the U.S. and have standard payment terms that generally require payment within 30 to 60 days. We have evaluated the creditworthiness of our customers, including Celgene, and determined them to be creditworthy. To date we have not experienced any losses with respect to our receivables.</span></div>
CY2018Q1	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	124184000	USD
CY2018Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-758605000	USD
CY2018Q3	us-gaap	Contract With Customer Asset Net Current ContractWithCustomerAssetNetCurrent	2631000	USD
CY2018Q3	agio	Collaboration Receivable Duefrom Related Parties Current CollaborationReceivableDuefromRelatedPartiesCurrent	3395000	USD
CY2018Q3	agio	Collaboration Receivable Other Current CollaborationReceivableOtherCurrent	440000	USD
CY2018Q3	us-gaap	Assets Current AssetsCurrent	695542000	USD
CY2018Q3	us-gaap	Assets Assets	929079000	USD
CY2018Q3	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	42141000	USD
CY2018Q3	us-gaap	Liabilities Current LiabilitiesCurrent	84746000	USD
CY2018Q3	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	66294000	USD
CY2018Q3	us-gaap	Liabilities Liabilities	168866000	USD
CY2018Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1012839000	USD
CY2018Q3	us-gaap	Stockholders Equity StockholdersEquity	760213000	USD
CY2018Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	929079000	USD
CY2018Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	82561000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	247515000	USD
CY2018Q3	us-gaap	Operating Expenses OperatingExpenses	114360000	USD
	us-gaap	Operating Expenses OperatingExpenses	330497000	USD
CY2018Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-99162000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-266123000	USD
CY2018Q3	us-gaap	Net Income Loss NetIncomeLoss	-94664000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-254234000	USD
CY2018Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.63
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-4.45
CY2018Q3	us-gaap	Net Income Loss NetIncomeLoss	-94664000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-254234000	USD
CY2018Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-94385000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-254964000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-254234000	USD
	agio	Increase Decrease In Contract With Customer Asset IncreaseDecreaseInContractWithCustomerAsset	2631000	USD
	agio	Increase Decreasein Collaboration Receivable Duefrom Related Parties Current IncreaseDecreaseinCollaborationReceivableDuefromRelatedPartiesCurrent	947000	USD
	agio	Increase Decreasein Collaboration Receivable Other Current IncreaseDecreaseinCollaborationReceivableOtherCurrent	440000	USD
CY2018Q3	agio	Increase Decrease In Contract With Customer Liability Related Party IncreaseDecreaseInContractWithCustomerLiabilityRelatedParty	-15749000	USD
CY2018Q3	us-gaap	Marketable Securities Realized Gain Loss MarketableSecuritiesRealizedGainLoss	0	USD
	us-gaap	Marketable Securities Realized Gain Loss MarketableSecuritiesRealizedGainLoss	0	USD
CY2017Q3	us-gaap	Marketable Securities Realized Gain Loss MarketableSecuritiesRealizedGainLoss	0	USD
	us-gaap	Marketable Securities Realized Gain Loss MarketableSecuritiesRealizedGainLoss	0	USD
	us-gaap	Reclassification From Accumulated Other Comprehensive Income Current Period Net Of Tax ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax	0	USD
	us-gaap	Reclassification From Accumulated Other Comprehensive Income Current Period Net Of Tax ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax	0	USD
CY2017Q3	us-gaap	Reclassification From Accumulated Other Comprehensive Income Current Period Net Of Tax ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax	0	USD
CY2018Q3	us-gaap	Reclassification From Accumulated Other Comprehensive Income Current Period Net Of Tax ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax	0	USD
CY2018Q3	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	724041000	USD
CY2018Q3	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	USD
CY2018Q3	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	2119000	USD
CY2018Q3	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	721922000	USD
CY2017Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	466415000	USD
CY2017Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	USD
CY2017Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	1389000	USD
CY2017Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	465026000	USD
	agio	Available For Sale Securities Non Current Minimum Liquidating Period AvailableForSaleSecuritiesNonCurrentMinimumLiquidatingPeriod	P12M
CY2018Q3	us-gaap	Availableforsale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions Greater Than Or Equal To One Year AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsGreaterThanOrEqualToOneYear	236	security
CY2017Q4	us-gaap	Availableforsale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions Greater Than Or Equal To One Year AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsGreaterThanOrEqualToOneYear	240	security
CY2018Q3	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue	659800000	USD
CY2017Q4	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue	439400000	USD
CY2018Q3	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	0	USD
CY2018Q3	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	788000	USD
CY2018Q3	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	75000	USD
CY2018Q3	us-gaap	Inventory Net InventoryNet	863000	USD
CY2018Q3	us-gaap	Inventory Write Down InventoryWriteDown	0	USD
CY2018Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	11748000	USD
CY2017Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	15693000	USD
CY2018Q3	agio	Accrued Research And Development Costs Current AccruedResearchAndDevelopmentCostsCurrent	10535000	USD
CY2017Q4	agio	Accrued Research And Development Costs Current AccruedResearchAndDevelopmentCostsCurrent	14849000	USD
CY2018Q3	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	2509000	USD
CY2017Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	3140000	USD
CY2018Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	511000	USD
CY2017Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	349000	USD
CY2018Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	25303000	USD
CY2017Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	34031000	USD
CY2017Q4	agio	Contract With Customer Contractual Adjustment Reserve ContractWithCustomerContractualAdjustmentReserve	0	USD
CY2017Q4	agio	Contract With Customer Rebate Reserve ContractWithCustomerRebateReserve	0	USD
CY2017Q4	agio	Contract With Customer Right To Recover Product Reserve ContractWithCustomerRightToRecoverProductReserve	0	USD
CY2017Q4	agio	Contract With Customer Total Allowances And Reserves ContractWithCustomerTotalAllowancesAndReserves	0	USD
	agio	Provision For Contractual Adjustments ProvisionForContractualAdjustments	360000	USD
	agio	Provision For Rebate Reserve ProvisionForRebateReserve	135000	USD
	agio	Provision For Right To Recover Product ProvisionForRightToRecoverProduct	106000	USD
	agio	Contract With Customer Reserve Provisions ContractWithCustomerReserveProvisions	601000	USD
	agio	Contract With Customer Contract Adjustment Recoveries ContractWithCustomerContractAdjustmentRecoveries	180000	USD
	agio	Contract With Customer Rebate Reserve Recoveries ContractWithCustomerRebateReserveRecoveries	0	USD
	agio	Contract With Customer Right To Recover Product Recoveries ContractWithCustomerRightToRecoverProductRecoveries	0	USD
	agio	Contract With Customer Reserve Recoveries ContractWithCustomerReserveRecoveries	180000	USD
CY2018Q3	agio	Contract With Customer Contractual Adjustment Reserve ContractWithCustomerContractualAdjustmentReserve	180000	USD
CY2018Q3	agio	Contract With Customer Rebate Reserve ContractWithCustomerRebateReserve	135000	USD
CY2018Q3	agio	Contract With Customer Right To Recover Product Reserve ContractWithCustomerRightToRecoverProductReserve	106000	USD
CY2018Q3	agio	Contract With Customer Total Allowances And Reserves ContractWithCustomerTotalAllowancesAndReserves	421000	USD
CY2018Q3	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	98000	USD
CY2018Q3	agio	Contract With Customer Allowance And Reserves Liability ContractWithCustomerAllowanceAndReservesLiability	323000	USD
CY2018Q3	agio	Contract With Customer Total Allowances And Reserves ContractWithCustomerTotalAllowancesAndReserves	421000	USD
CY2017Q4	us-gaap	Contract With Customer Asset Net ContractWithCustomerAssetNet	0	USD
	agio	Contractwith Customer Asset Revenue Recognized ContractwithCustomerAssetRevenueRecognized	5328000	USD
	agio	Contract With Customer Asset Proceeds From Collection Of Receivables ContractWithCustomerAssetProceedsFromCollectionOfReceivables	2697000	USD
CY2018Q3	us-gaap	Contract With Customer Asset Net ContractWithCustomerAssetNet	2631000	USD
	us-gaap	Revenue Recognition Multiple Element Arrangements RevenueRecognitionMultipleElementArrangements	<span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">On January 1, 2018 we adopted ASC 606 under the modified retrospective method. Prior to January 1, 2018 we accounted for the Collaboration Agreements under ASC 605-25, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;">Multiple Element Arrangements.</span><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;">Accounting under ASC 606</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">In adopting ASC 606, we applied the practical expedient that permits aggregating the effect of all contract modifications that occurred prior to January 1, 2018. No other practical expedients were used. Similar to the accounting under ASC 605-25, the 2016 Agreement was determined to be a modification of the 2010 Agreement and the AG-881 Agreements. In determining the appropriate amount of revenue to be recognized under ASC 606, we performed the following steps: (i) identified the promised goods or services in the contract; (ii) determined whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract; (iii) measured the transaction price, including the constraint on variable consideration; (iv) allocated the transaction price to the performance obligations; and (v) recognized revenue when (or as) we satisfied each performance obligation.</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">As part of the accounting for these arrangements, we must develop assumptions that require judgment to determine the stand-alone selling price, or SSP, for each performance obligation identified in the contract. We use key assumptions to determine the SSP, which include forecast of revenues, development timelines, reimbursement rates for personnel costs, discount rates and probabilities of technical and regulatory success.</span></div>
CY2018Q3	agio	Collaboration Revenue Revenue From Related Parties CollaborationRevenueRevenueFromRelatedParties	8732000	USD
CY2017Q3	agio	Collaboration Revenue Revenue From Related Parties CollaborationRevenueRevenueFromRelatedParties	10643000	USD
	agio	Collaboration Revenue Revenue From Related Parties CollaborationRevenueRevenueFromRelatedParties	42478000	USD
	agio	Collaboration Revenue Revenue From Related Parties CollaborationRevenueRevenueFromRelatedParties	32497000	USD
CY2018Q3	us-gaap	Research And Development Arrangement Contract To Perform For Others Compensation Earned ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned	0	USD
CY2017Q3	us-gaap	Research And Development Arrangement Contract To Perform For Others Compensation Earned ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned	1078000	USD
	us-gaap	Research And Development Arrangement Contract To Perform For Others Compensation Earned ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned	0	USD
	us-gaap	Research And Development Arrangement Contract To Perform For Others Compensation Earned ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned	6343000	USD
CY2018Q3	agio	Revenue Remaining Performance Obligation C Stone Agreement RevenueRemainingPerformanceObligationCStoneAgreement	1300000	USD
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	5577562	shares
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	49.58
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1293020	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	78.35
CY2018Q3	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	7555000	USD
	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	23472000	USD
CY2018Q3	us-gaap	Contract With Customer Performance Obligation Satisfied In Previous Period ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod	219000	USD
	us-gaap	Contract With Customer Performance Obligation Satisfied In Previous Period ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod	762000	USD
CY2018Q3	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	115900000	USD
CY2018Q3	us-gaap	Revenue Recognition Milestone Method Revenue Recognized RevenueRecognitionMilestoneMethodRevenueRecognized	0	USD
CY2017Q3	us-gaap	Revenue Recognition Milestone Method Revenue Recognized RevenueRecognitionMilestoneMethodRevenueRecognized	0	USD
	us-gaap	Revenue Recognition Milestone Method Revenue Recognized RevenueRecognitionMilestoneMethodRevenueRecognized	0	USD
	us-gaap	Revenue Recognition Milestone Method Revenue Recognized RevenueRecognitionMilestoneMethodRevenueRecognized	0	USD
CY2018Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	5485314	shares
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	1078290	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	24.13
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	306978	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	76.15
CY2017Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	12207000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	55170000	USD
CY2018Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	59.88
CY2018Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	2774270	shares
CY2018Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	54.67
CY2018Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	5485314	shares
CY2018Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	59.88
CY2018Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	24193000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	35128000	USD
CY2018Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	24193000	USD
CY2017Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	12207000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	55170000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	35128000	USD
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	6111413	shares
CY2018Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	6111413	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5945959	shares
CY2017Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5945959	shares

Files In Submission

Name	View Source	Status
0001439222-18-000018-index-headers.html	Edgar Link	pending
0001439222-18-000018-index.html	Edgar Link	pending
0001439222-18-000018.txt	Edgar Link	pending
0001439222-18-000018-xbrl.zip	Edgar Link	pending
agio-20180930.htm	Edgar Link	pending
agio-20180930.xsd	Edgar Link	pending
agio-20180930_cal.xml	Edgar Link	unprocessable
agio-20180930_def.xml	Edgar Link	unprocessable
agio-20180930_htm.xml	Edgar Link	completed
agio-20180930_lab.xml	Edgar Link	unprocessable
agio-20180930_pre.xml	Edgar Link	unprocessable
agiossymble.jpg	Edgar Link	pending
exhibit10-1x09x30x2018.htm	Edgar Link	pending
exhibit10-2x09x30x2018.htm	Edgar Link	pending
exhibit31-1x09x30x2018.htm	Edgar Link	pending
exhibit31-2x09x30x2018.htm	Edgar Link	pending
exhibit32-1x09x30x2018.htm	Edgar Link	pending
exhibit32-2x09x30x2018.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$AGIO
Agios Pharmaceuticals Inc Stock $agio

2018 Q4 Form 10-Q Financial Statement

#000143922218000018 Filed on November 01, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AGIO Agios Pharmaceuticals Inc Stock $agio

2018 Q4 Form 10-Q Financial Statement

#000143922218000018 Filed on November 01, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AGIO
Agios Pharmaceuticals Inc Stock $agio